Jenny Hendriks

Head Biomarkers

Janssen (Netherlands)

Netherlands

Research Interests

Explore related searches

Professors in Netherlands Professors in Immunology Immunology professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Jenny Hendriks is the Head of Biomarkers at Janssen in the Netherlands. Her research focuses on vaccine-induced immune responses, particularly in the context of COVID-19, Ebola, and HIV-1 vaccines. Recent articles authored by her include studies on antibody responses and safety evaluations of various vaccine regimens, contributing valuable insights to the field of immunology.

Articles (17)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

UNITED STATES

View details

Associate Professor

Wayne State University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Jenny Hendriks

Research Interests

Explore related searches

Contact this professor

About

Articles (17)

ALVAC-prime and monomeric gp120 protein boost induces distinct HIV-1 specific humoral and cellular responses compared with adenovirus-prime and trimeric gp140 protein boost.

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trial

Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial

Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study

Assessment of antibodies against platelet factor 4 following vaccination with adenovirus type 26-vectored vaccines

SARS-CoV-2 Viral Load in the Nasopharynx at Time of First Infection Among Unvaccinated Individuals

The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia

Safety and Immunogenicity of Accelerated Heterologous Two-dose Ebola Vaccine Regimens in Adults With and Without HIV in Africa

Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults

Absolute quantitation of binding antibodies from clinical samples

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical Trial

Ad26.COV2.S COVID-19 Vaccine Safety And Immunogenicity in Adolescents 16–17 Years of Age

Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases

Risk of COVID-19 after natural infection or vaccination

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

Collaborators (9)

Thomas Martin

Stephen Walsh

David R. Andes

Cynthia Monaco

Ying Huang

Timothy Hatlen

Josh Knowles

Eric D'Ortenzio

Paul Kilgore

Make your next move.